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1. INTRODUCTION 
  Chronic kidney disease (CKD) encompasses group of distinct 
pathophysiological processes which are associated with abnormal kidney 
functioning  and progressively reducing Glomerular Filtration rate (GFR). 
  Various pathological processes in CKD ultimately results in loss of  
Renal metabolic, excretory, endocrine, and synthetic functions due to 
accumulation of various protein nitrogenous substances. 
  The widespread cause of mortality in patients with CKD is spectrum 
of cardiovascular diseases. The prevalence of cardiovascular morbidity in 
patients of age group 25-34 years with CKD is 500 times that of people 
without CKD in similar age group and race. 
  The initial stages of CKD are mostly managed by Primary Care 
Physicians and they have a pivotal role in delaying the progression of CKD 
to ESRD by addressing various co-morbidities associated with CKD by 
identifying and intervening them early. 
  Two of such important co-morbidities being lipid dysfunction and 
Thyroid dysfunction in patients with CKD. 
  Hyperlipidemia , an abnormally high level of lipids in blood ,is a well 
known risk factor for early Atherosclerosis causing various cardiovascular 
diseases ,is frequently seen in patients with CKD. 
  Indian studies demonstrating  pathophysiological relationship of CKD 
with Lipid profile have quoted almost nil Lipid profile abnormalities in 
2 
CKD to pathophysiologically significant alterations in lipid profile in 
patients with CKD like high triglycerides and low HDL level. 
  B Shah, S Nair studied the occurrence of lipid profile abnormalities in 
CKD and have demonstrated the significant hypertriglyceridemia in patients 
with CKD. 
  Increased level of triglycerides, total cholesterol and low levels of 
HDL-C  in patients with CKD managed conservatively has been shown in 
study by Sumathi M.E, Manjunath, M.Tempad. 
  There is also an evidence of thyroid hormone dysfunction in patients 
with CKD.CKD causes alteration in synthesis, secretion, metabolism & 
elimination of Thyroid hormones. 
        Iodine an important element in the synthesis of thyroid hormone is 
removed from circulation by glomerular filtration under physiological 
conditions .In CKD, the progressively decreasing GFR leads to 
accumulation of  Iodine in blood which ultimately leads to decreased 
thyroid hormone synthesis by ‘Wolff Chaikoff effect’. 
        This results in subnormal levels of serum total & free T3 concentration 
and normal reverse T3  & free T4  levels. But, TSH level is mostly unaltered 
in CKD. Patients may also have symptoms of hypothyroidism in CKD. 
       Studies in the past have demonstrated all types of thyroid 
abnormalities like hypothyroidism, hyperthyroidism and euthyroidism in 
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patients with CKD. The prevalence of hypothyroidism is 0.9% in patients 
with ESRD. Goitre is also noted in patients with CKD. 
        Because of this pathologically significant occurrence of dyslipidemia 
and thyroid abnormalities in patients with CKD,  a prospective  study of  
lipid profile & thyroid abnormalities in CKD  has been undertaken in the 
Department of General Medicine, Tirunelveli Medical College and hospital, 
Tirunelveli.  
 
 
 
 
 
 
               
 
 
 
 
 
  
  
 
 
 
 
AIMS AND OBJECTIVES 
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2. AIMS AND OBJECTIVES OF THE STUDY 
 
 To determine Thyroid profile of CKD patients and compare them 
with healthy controls 
 
 To determine Serum Lipid profile of CKD patients and compare them 
with healthy controls 
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3. REVIEW OF LITERATURE 
 
3.1 FUNCTIONS OF THE KIDNEY 
The important functions of the kidney are: 
 Excretion of waste products of metabolism, toxins and few drugs. 
 Strict regulation of fluid and electrolyte balance. 
 Maintenance of acid – base balance. 
 Maintenance of body fluid osmolality and electrolyte composition. 
 Maintaining  blood pressure. 
It also contributes to secretion, metabolism and excretion of few 
hormones. Its important endocrine functions are production of renin, 
erythropoietin, prostaglandins and endothelins. 
The important metabolic function of the kidney is the 1hydroxylation 
of 25 hydroxy D3 and aids in vitamin D synthesis. It regulates of 
erythrocyte production by secreting erythropoietin. 
 
DETERMINANTS OF GFR1  
 Cockcroft and Gault formula is most commonly used to estimate GFR. 
It goes as: 
           Estimated creatinine clearance in ml/min = (140 – age) X Lean body 
weight (kg) 72X plasma creatinine (mg/dl). 
           Multiply by 0.85 for women. 
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3.2 CHRONIC KIDNEY DISEASE 
Definition 
             Signs of kidney damage for more than or equal to three months as 
explained  by anatomical or physiological abnormalities of the kidney, with 
or without reduction in GFR. 
            GFR value below 60 ml/min/1.33m2  for more than or equal to three 
months with or without other signs of kidney damage. 
Causes of chronic kidney disease 
  The most prevalent cause of chronic kidney disease in developed 
countries is diabetic glomerulosclerosis while in developing countries being 
primary glomerulonephritis. 
 
Major etiologies of CKD 
 DiabeticNephropthy 
 Glomerulonephritis 
 Hypertension – associated CKD 
 Autosomal dominant polycystic kidney disease 
 Medullary cystic kidney 
 Tubulointerstitial nephropathy. Etc., 
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 STAGES OF CKD:2 
 
 
 
 
 
 
                   
 
CLASSIFICATION OF CKD: 
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CLASSIFICATION OF CKD BY PATHOLOGY AND ETILOGY: 
 
PATHOLOGY: 
 Diabetic Glomerulosclerosis 
 Glomerular diseases(Primary 
and secondary) 
Pproliferative 
Glomerulonephritis 
 Minimal change disease 
 Membranous Nephropathy 
 Focal Glomerular sclerosis 
 Fibrillary Glomerular 
disease 
 Hereditary Nephritis 
 Diseases affecting vessels: 
large size vessels 
Medium size vessel 
(Nephrosclerosis) 
Small size vessels 
(Microangiopathy) 
 Tubulointerstitial diseases: 
Reflux nephropathy 
Tubulointerstitial nephritis 
Obstructive nephropathy 
Myeloma kidney 
 Cystic Kidney diseases: 
 Polcystic kidney disease 
 Von-Hippel Lindau disease 
 Tuberous sclerosis 
 Medullary cystic Kidney 
ETIOLOGY: 
 Diabetes mellitus 
 commonly idiopathic 
 Hypertension 
 SLE,Bacterial 
Endocarditis,HIV,  
 Hepatitis B and C virus, 
 Hodgkin,s disease 
 Drug toxicity 
 Solid tumours, 
 Light chain diseases 
 Amyloidosis 
 Alport’s syndrome 
 Aortoarteritis 
 Renal artery stenosis 
 Vasculitis 
 Hemolytic Uraemic syndrome 
 Sickle cell disease with or 
without crisis 
 Vesico Ureteric Reflux disease 
 Stones,Malignancy,Prostatic 
enlargement 
 Sarcoidosis 
 Infections, drugs and toxins 
 Multiple Myeloma 
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PATHOPHYSIOLOGY OF CKD: 
The two underlying pathophysiologic manifestations in CKDS are: 
1. Mechanisms that initiate pathological processes in CKD specific to 
particular etiology 
2. Mechanisms involving hypertrophy & hyperfiltration of the left out 
viable nephrons following long term reduction in renal mass, 
whatever may be the cause . 
3. Various mediators attributed to nephron loss are: 
 Cytokine  
 Various Vasoactive hormones 
Growth factors 
          Finally short term adaptations like hypertrophy and hyperfiltration in 
the remaining viable nephrons becomes maladaptive  as the pressure 
increases and flow within the nephron susceptible to glomerular 
architectural distortion, podocyte dysfunction and interruption of filtration 
barrier which ultimately leads to sclerosis and dropout of remaining viable 
nephrons. Increase in renin- angiotensin system contributes to both initiative 
and subsequent maladaptive hypertrophy and sclerosis. 
  The peculiar property of kidney in CKD is the compensatory and 
adaptive mechanism which makes the condition asymptomatic until the 
GFR falls to 10-15 ml/min and life sustaining renal excretory and 
homeostatic functions continues until GFR  is less than 5 ml/minute making 
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the disease truly a silent killer. Different Hypotheses explaining the 
pathological processes in CKD are: 
 
INTACT NEPHRON HYPOTHESIS: 
             In CKD, there is progressive loss of functioning nephrons. The 
remaining few viable nephrons try to compensate for the lost nephrons and 
tends to hypertrophy which results in summed up work load, so overall 
functional loss is reduced. This adaptive mechanism is called as 
compensatory hyperfiltration. 
              A study conducted in renal transplant donors, there is increased  
glomerular filtration rate upto 40% and increase in renal plasma flow in the 
remaining kidney within weeks after nephrectomy. The GFR increases to 
about 70% of prenephrectomy range. 
              Increased perfusion of remaining viable nephrons causes 
production of increased volume of glomerular filtrate. The tubules responds 
to increased changes by excreting fluids and solutes in larger amounts which 
helps in maintaining external balance. This efficient integration of functions 
of glomerulus and tubules is known as “Glomerulotubular balance” which is 
preserved until later stages of the disease. 
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TRADE OFF HYPOTHESIS: 
        Trade off hypothesis states that, adaptation emerging in CKD may 
control one abnormality, but only in such a way to produce other changes 
which is characteristic of uraemic syndrome. The mechanism of which is 
not precisely known. It is described in hormones like atrial natureteric 
peptide,vasopressin, parathromone and solutes including sodium, potassium, 
phosphate and others. 
 
MIDDLE MOLECULE HYPOTHESIS: 
            Patients who are all treated with maintenance peritoneal dialysis, 
have a conflict between the degree of azotemia and presentation of the 
disease symptoms. In patients undergoing maintanence peritoneal dialysis, 
inspite of higher renal parameters the symptoms of uraemia are mild and 
they are less prone to the development of peripheral neuropathy when 
compared with the same counterparts undergoing hemodialysis.  
This suggests that toxicity is mainly dependant upon the presence of  
high molecular weight substances which are readily removed in Peritoneal 
dialysis (50-500 daltons) than in hemodialysis. 
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FLUID, ELECTROLYTES AND ACID BASE DISORDERS 
 Sodium and water homeostasis 
            In CKD patients, ECF (extracellular fluid) volume is maintained in 
the physiological range till the very late stages of CKD. Fractional excretion 
of sodium is increased in patients with CKD so that absolute sodium 
excretion is unchanged until late stages. 
           Total body content of sodium is important determinant in the 
extracellular fluid volume, so any impairment in sodium balance will lead to 
volume overload or volume depletion .Volume depletion is caused by 
sudden salt restriction in CKD which is frequently seen with 
tubulointerstitial diseases (salt losing nephropathies). On contrary, retention 
of sodium leads to peripheral edema, cardiac failure and arterial 
hypertension. 
    Diuretics are frequently used to cause natriuresis in CKD patients. 
Thiazide diuretics have a minimal role. Loop diuretics in higher doses are 
recommended in CKD.  Metalazone can also be combined with loop 
diuretics, which inhibits sodium chloride co–transporter present in the distal 
convoluted tubule of the kidney, favouring increased sodium excretion. 
Potassium homeostasis: 
     In CKD, excretion of potassium in kidneys is reduced which is in 
proportion to loss of glomerular filtration. The adaptive mechanisms being 
increased secretion of aldosterone and significantly high extrarenal 
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(intestinal) excretion of potassium to maintain potassium homeostasis until 
the glomerular filtration falls to10 ml/minute. 
   Drugs such as ACEI, ARBs, aldosterone antagonist, NSAIDs 
frequently cause hyperkalemia in CKD. The other causes include diet rich 
with potassium, hemolysis, Hemorrhage, high protein breakdown, metabolic 
acidosis. hyperkalemia is managed with dextrose with insulin, salbutamol 
(beta 2 agonist) nebulisation, 10% calcium gluconate (if 
electrocardiographic changes are obvious). 
         Hypokalemia is rare in CKD, if it present, it is mainly seen with 
excessive diuretic therapy, extrarenal (gastrointestinal) loss, reduced intake 
of potassium. 
15 
Complications of CKD 
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Metabolic acidosis 
         Non anion gap metabolic acidosis is frequently seen in earlier stages 
of CKD. In Later stages of CKD, the total daily urinary acid excretion is 
reduced to  30 – 40 mmol and anion gap of not more than 20mEq/L is seen 
frequently. 
 Changes in Haematological System:3 
             In CKD, there is normocytic normochromic anaemia due to 
decreased renal synthesis of erythropoietin, a hormone which involved in 
stimulation of bone marrow red blood cell production. 
   The various causes of anaemia in CKD are: 
 Decreased RBC life span 
 Iron deficiency 
 Vitamin B12 and folate deficiency 
 Uraemia induced platelet dysfunction and bleeding 
 Chronic inflammation 
 Aluminium toxicity 
 Renal osteodystrophy and bone marrow fibrosis 
 Hyperparathyroidism   
 Hemorrhage 
Bone Changes4 
     Mineral metabolism is affected in CKD leading to metabolic bone 
disease causing dual skeletal and extraskeletal abnormalities 
17 
    Mineral and bone metabolism disturbances in CKD manifests as:  
Calcium, phosphorous, parathormone and vitamin D metabolic dysfunction. 
Abnormalities in  bone turn over, mineralisation. Vascular and soft tissue 
calcification. 
 
CKD and heart: 
        In CKD, the most common cause of morbidity and mortality is 
cardiovascular diseases. Myocardial ischemia, Uremia, left ventricular 
hypertrophy, which occur in CKD can cause congestive cardiac failure and 
pulmonary edema, due to raised permeability of  pulmonary alveolar 
capillary membrane in lungs. 
Peripheral neuropathy: 
          The classical presentation  peripheral neuropathy is seen in advanced 
stages (stage IV and V) of CKD. Sensory neuropathy is more common than 
motor neuropathy. The lower extremities are more commonly affected  than 
upper extremities and distal part of limb is more affected than proximal part. 
Uraemic encephalopathy: 
          It manifests as acute or subacute organic brain syndrome when 
glomerular filtration falls to less than 10% of normal. The clinical 
symptoms & signs of uraemic encephalopathy includes altered level 
consciousness, psychomotor disturbances and disturbances of thinking, 
memory, speech, emotion and perception. 
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Restless leg syndrome: 
           The restless leg syndrome is one of the manageable causes of sleep 
disturbance in end stage renal disease. It is a neurological motor movement 
disorder of limbs associated with sleep disruption. It presents as unpleasant 
sensation in legs and feet requiring frequent limb movement.The urge to 
move limbs is more during rest and is relieved with movements. 
Gastrointestinal abnormalities: 
           Uraemic gastritis, peptic ulcer disease and mucosal ulcerations can 
occur in the gastrointestinal tract in patients with CKD. 
Metabolic disturbances: 
          Fasting increased insulin production can cause spontaneous 
hypoglycemia  in patients with end stage renal disease . Insulin requirement 
may be reduced in late stages of CKD. The other abnormalities being 
impaired glucose tolerance and decreased insulin sensitivity. 
Dermatological abnormalities: 
            The frequent dermatological changes seen in CKD include pruritis 
and skin excoriation. Dysfunctional calcium and phosphorus metabolism 
can cause  vascular and soft tissue calcification which ends uo in skin and 
soft tissue necrosis. It is known as calciphylaxis seen solely due to 
secondary hyperparathyroidism. 
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3.3 THYROID 
ANATOMY OF THYROID GLAND: 
The thyroid gland is made of  two lobes united by an isthmus. It lies  
in front of trachea in  between suprasternal notch and cricoid cartilage. 
Weight being 12 to 20 grams and is larger in females than in males. Two 
pairs of  parathyroid glands are situated back at each pole of thyroid gland, 
which synthesizes and secretes parathormone. 
 
PHYSIOLOGY OF THYROID HORMONES: 
                 The hormones produced and secreted by thyroid gland are T3 
(Triiodothyronine) and T4 (Thyroxine). Thyroid hormones play a important 
role in cell differentiation during development and maintainence of  
metabolic homeostasis in adults5 
.  The secretion of T3 and T4 are mainly under the control by Thyroid 
Stimulating Hormone, produced by the master gland, Pitutary Gland. 
Thyrotropin releasing hormone (TRH) ,produced by Hypothalamus, 
stimulates the secretion of T3 and T4. The hypothalamic secretion TRH and 
pituitary secretion of TRH are under negative feedback control of free T4 
and free T3.6 
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Thyroid hormone has many effects: 
1. Growth     
2. Developmental    
3. Renal effects 
 
Renal Effects: 
 -Increased sodium tubular reabsorption                                                                        
 -Stimulates renin secretion 
 -Control sulfate homeostasis 
 -Increase calcium tubular reabsorption. 
  The first step in thyroid hormone production  is uptake of iodide. 
Then iodide trapping happens by which iodide is actively transported  into 
thyroid cell,where it is “oxidised” into iodine. It then combines with 
tyrosine to produce monoiodotyrosine (MIT) and diiodotyrosine (DIT). 
          MIT combines with DIT to form T3 whereas combination of two DIT 
forms T4. Up until secretion thyroid hormones T3 and T4 are in bound form 
with thyroglobulin. Thyroid peroxidase, the enzyme,  catalyzes oxidation, 
iodination and coupling reactions. 
IODIDE-- ENTERS THYROID CELL--- IODINE + TYROSINE--- MIT+DIT 
 
MIT+DIT= T3 
DIT +DIT=T4 
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FIGURE-2: BIOSYNTHESIS AND SECRETION OF THYROID  HORMONE 
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Thyroid hormone once secreted  into the blood stream , most of T3 
and T4 binds with plasma proteins namely, thyroxine – binding globulin and 
thyroxine – binding prealbumin and albumin. T4 mainly binds with 
thyroxine – binding globulin whereas T3 binds mainly with albumin. The 
plasma binding proteins delays hormonal clearance. Increases the 
circulating availability of  hormone, so that it can be  delivery to selected 
tissue sites when if need. The rest of the thyroid hormones are transported in 
unbound form as free T3 and free T4 .In circulation, there is equilibrium 
between bound and free form. In peripheral circulation, the enzyme 5’ 
Deiodenase converts 1/3rd  of T4 to T3 and 5 deiodenase converts 45% of 
T4 to rT3. Only 13% of T3 is produced and released directly from the 
thyroid gland, and the remaining 87% is formed from T4. 
             Half life of T4 is more than that of T3, whereas potency of T3 is 
more  than that of T4. The half life of T4 is seven days and T3 is 10 to 24 
hours. 
          Thyroxine is secreted at a rate of  80 to 90 micrograms/day, tri-
iodothyronine at 4 to 5 micrograms/day and reverse T3 is 1 to 2 
microgram/day. The plasma level of total T3 is maintained at 0.12 
microgram/dl and T4 is 8 microgram/dl. 
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THYROID AND KIDNEY: 
 Thyroid hormones plays an important role in renal development and 
physiology7,8,9,10,11. On the other hand kidney disease can lead to thyroid 
abnormalities. 
Effects of thyroid hormone on renal development: 
 It aids in cell growth and protein synthesis. The functioning renal 
mass (kidney to body mass ratio) is influenced by thyroid hormone. In 
hypothyroidism this ratio is reduced  and increased in hyperthyroidism in 
which there is protein breakdown and finally renal atrophy occurs in  severe 
hyperthyroidism.Thyroid hormone causes increased activity of Na-P co-
transporter, Na-H exchanger and Na/K ATPase in the proximal convoluted 
tubule. 
Effect of thyroid hormone on renal physiology: 
             Thyroid hormones affects  renal function directly and indirectly. 
The indirect effect is shown upon  cardiovascular system and renal blood 
flow. The direct effect is that it acts upon on glomerular filtration rate, 
tubular secretory and reabsorptive function and hormonal influences. 
         The thyroid hormone favours and increases the activity of 
Na/K/ATPase in Renal proximal convoluted tubule and also causes 
increased sodium reabsorption. Thyroid hormones  also has effects  on  
tubular  potassium  permeability12and  tubular  calcium reabsorption13. By 
adrenergic regulation14, thyroid hormones also influences the renin 
angiotensin aldosterone(RAAS)  axis and influences Renin release15. 
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TABLE 4. EFFECT OF THYROID DYSFUNCTION ON THE KIDNEY 
 Hypothyroidism Hyperthyroidism 
   
Glomerular filtration Decreased Increased 
   
Serum creatinine Increased Decreased 
   
Renal plasma flow Decreased Increased 
   
Sodium reabsorption Decreased Increased 
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Hypothyroidism and Renal function 
          In hypothyroidism features like increased serum creatinine level 
4
,decreased glomerular filtration(GFR) and renal plasma flow are there. By 
the direct effect of thyroid hormone on cardiovascular system , there is rise 
in peripheral vascular resistance, poor myocardial contractility and stroke 
volume and its effect on metabolism leads to  hyperlipidemia. The indirect 
effects of thyroid hormones happen through insulin like growth factor type I 
and vascular endothelial growth factor 
The most frequent  electrolyte abnormality seen in hypothyroidism is 
hyponatremia.(Decreased Serum Sodium ). It is predominantly  due to 
decreased GFR, producing reduced water delivery to distal tubules in 
kidney. The other possible cause being  inappropriate ADH secretion .The 
proximal tubular reabsorption of sodium ,water  and chloride are decreased. 
The microscopic changes such as glomerular basement membrane 
thickening and mesangial matrix expansion are frequently noticed  in 
hypothyroidism, which causes decremental  renal blood flow. The 
sensitivity of collecting duct to vasopressin receptor is regulated inversely, 
thus causing increased free water reabsorption. There is reduced production 
of Cystatin –C, so that serum levels of Cystatin – C is  subnormal in 
hypothyroidism. Treatment of hypothyroidism with levothyroxine could 
reverse most of the above mentioned changes. 
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Hyperthyroidism and renal function 
Thyroid hormones have positive chronotrophic (Heart Rate)16, 
inotrophic17 effect( Contractility) and also reduced systemic vascular 
resistance,18 which indirectly leads to increased renal blood flow. 
The other indirect effects of thyroid hormones to increase  blood flow 
to kidney are by raised endothelial making of nitric oxide19 along with 
decreasing production of endothelin, a potent  renal vasoconstrictor. 
In hyperthyroidism, GFR is raised by about 18 – 25%56, this is due to 
raised renal blood flow. There is also increased beta adrenergic activity and 
more positive stimulation of renin angiotensin aldosterone system due to 
hyperthyroidism. The increased renin angiotensin aldosterone activity 
causes afferent arteriolar vasodilatation and efferent arteriolar 
vasoconstriction which consequently produces increased glomerular 
filtration rate (GFR). 
 In hyperthyroidism, there is  stimulated  activity of  apical Na-H 
exchanger, basolateral Na/K/ ATPase, Na – Pi co-transporter. 
In  hyperthyroidism,  serum  creatinine  is  proportionately  reduced  
due to increased glomerular filtration(GFR)  and fall in overall muscle 
mass61. Due to glomerular hyperfiltration, there is a raise  in 24 hour – 
urinary protein excretion. 
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CKD and thyroid function abnormalities 
   Hyperthyroidism favours progression of CKD by various mechanisms 
which includes, 
 It causes intraglomerular hypertension which produces increased 
filtration pressure and consequent raised filtration. 
 It  predisposes to proteinuria which may cause direct renal injury. 
 Inverse regulation of superoxide dismutase and raised mitochondrial 
energy metabolism causes more free radical generation and 
subsequent renal injury. 
 Oxidative stress. 
  One of  the earliest thyroid dysfunction seen among chronic kidney 
disease patients is   low level of T3 hormone (particularly total T3 than 
Free T3).  
This is called as low T3 syndrome. 
Low T3 syndrome occurs in CKD because of 
 Persistent metabolic acidosis 
 Fasting state 
 Protein malnutrition 
 Decresed peripheral conversion of T4 to T3 
 Iodothyronine deiodination 
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       The inflammatory cytokines like tumor necrosis factor alpha (TNF 
alpha) interleukin – 1 (IL -1) .In CKD, patient inhibits the expression' of 
enzyme type 1,5  deiodinase, which is required for peripheral conversion of 
T4 to T3. 
 There is raised serum iodine level due to dysfunctional renal 
handling, Leading to Wolff – Chaikoff effect. 
       There is decreased  iodide excretion resulting in raised serum iodide 
level and iodine content of thyroid gland which sebsequently produces 
enlargement of thyroid gland. There is more prevalence of Goitre, thyroid 
nodule, thyroid carcinoma in chronic kidney disease patients when 
compared to general population. 
      The CKD mediated thyroid function abnormalities are reversible after 
renal transplantation.  Within the first three to four months of Renal 
Transplantation  low T3 and low T4 level  are reversed. 
 
Other renal diseases associated with thyroid dysfunction 
 Membranous nephropathy20,21. 
 Minimal change disease22. 
 Ig A nephropathy23. 
 Membranous proliferative glomerular nephritis24. 
 Tubulointerstitial nephritis and uveitis25. 
       
29 
DIAGNOSIS OF PRIMARY THYROID DISEASES  
Recent studies have shown that there is more  prevalence of 
hypothyroidism in chronic kidney disease. Since several symptoms of both 
hypothyroidism and chronic kidney disease are similar in clinical picture, 
there is considerable difficulty in differentiating both conditions on clinical 
background alone. So, all the CKD patients with symptoms suggestive of 
hypothyroidism should be routed to  hypothyroidism screening. 
  The diagnosis of hypothyroidism should be made only if the 
following criteria exist: 
 There should be a elevated basal TSH value of > 20 µIU/m1. 
 Dual total and free T4 level should be distinctly low in the presence 
of normal TBG. 
 Existence of anti thyroid antibodies can provide clue for 
hypothyroidism. 
            Reverse T3 is not very useful because it is reduced in CKD. 
            In CKD, primary hyperthyroidism is exceedingly rare. This 
condition should be diagnosed with, 
 Raised serum total and free T4 concentration. 
 Reduced serum TSH values. 
             High serum T4 level with low T3 in the presence of CKD should 
make the presence of T4 thyrotoxicosis. This is due to suppression of serum 
T3 level in low T3 syndrome but serum T4 remains unaffected. 
30 
MANAGEMENT 
  There are sample studies which have been done in patients with the 
Low T3 syndrome in order to manage and correct the thyroid profile by 
admionitration of Levothyroxine and Triiodothyronine 
  Gregory Brent et al26 conducted a study in non thyroidal illness 
patients. They managed  all the patients with serum total T4 less than 5 tg/dl 
with 1.5 mcg/Kg of levothyroxine for upto 2 weeks. There is significant 
raise in thyroxine level in treated patients. 
There is also significant surge in serum T3 levels. Unfortunately, 
increased mortality was seen in the treatment group on day 5-17. 
Carter et al studied effects of administration of Triiodothyronine in 
the patients with CKD. The study stated that there is no change in serum T3 
level over a period of 3 months. The mean serum T4 and TSH levels were 
altered significantly. But there was no subjective improvement appreciated 
in this group of patients. 
 Based on the fore-mentioned observations, it has been suggested that 
low serum T3 level in patients with CKD has its metabolically protective 
effect and it is interpreted as a functional adaptation to a reduced basal 
metabolic rate (BMR) and to preserve energy in an adverse environment. 
Because of that, this condition has been renamed as “Thyroid hormone 
adaptation syndrome”. 
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There is decreased TSH level and increased catabolism, seen on 
administration with T4 or T3. Hence, giving thyroid hormone is non-
beneficial in patients with CKD. The study also shows that there is raised  in 
mortality with the treatment. So, thyroid hormone replacement should be 
avoided in CKD patients unless true hypothyroidism is evident. 
PROGNOSIS 
           The magnitude of the thyroid dysfuncion that occurs in  patients 
fulfilling the criteria for chronic kidney disease(CKD), in general shows the 
severity of the illness. The prognosis is poor in patients with low  levels of 
serum T3 and T4 or TSH concentration. Studies have stated that there  is 
reversal thyroid function abnormalities in CKD patients post renal 
transplantation. 
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3.4 DYSLIPIDEMIAS 
The  population and studies have shown that total and low-density 
lipoprotein (LDL)-cholesterol values are two of the most important 
independent predictors of cardiovascular morbidity and mortality 27 Factors 
contributing to elevated triglycerides in the general population include: 
obesity, physical inactivity, cigarette smoking, excess alcohol intake, type 2 
diabetes, chronic renal failure, and estrogen 
 
ATP III Classification of  Total, LDL and HDL Cholesterol(mg/dL) 
Total Cholesterol 
<200mg/dL           Desirable 
200-239mg/dL Borderline high 
>240mg/dL            High 
LDL Cholesterol 
<100mg/dL           Optimal 
100-129mg/dL above optimal 
130-159mg/dL Borderline high 
160-189mg/dL High 
>190mg/dL           Very high 
HDL Cholesterol 
 <40mg/dL           Low 
 >60mg/dL           High 
Triglycerides 
 <150 mg/dL Normal triglycerides 
150-199 mg/dL Borderline-high 
200-499mg/dl High 
>500 mg/dL           very high 
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Pathways of Lipid Transport 
Two pathways of lipid transport are: 
Exogenous Pathway 
Dietary triglycerides are hydrolyzed within the intestinal lumen and 
emulsified with bile acids to form micelles. Cholesterol is esterified in the 
enterocyte to form cholesteryl esters . Nascent chylomicrons are secreted 
into the intestinal lymph and delivered via the thoracic duct. The particles 
encounter lipoprotein lipase (LPL).The triglycerides are hydrolyzed by LPL, 
and free fatty acids are released. The released free fatty acids are taken up 
by adjacent myocytes or adipocytes and either oxidized to generate energy 
or stored as triglyceride. The chylomicron progressively shrinks in size 
creating chylomicron remnants, which are rapidly removed from the 
circulation by the liver.  
 
Endogenous Pathway 
 The triglycerides of VLDL are derived from the esterification of 
long-chain fatty acids. The packaging of hepatic triglycerides with the 
components of the nascent VLDL particle (apoB-100, cholesteryl esters, 
phospholipids and vitamin E, requires the action of the enzyme microsomal 
triglyceride transfer protein (MTP).After secretion into the plasma, VLDL 
acquires multiple copies of apoE and apolipoproteins of the C series. As 
with chylomicrons, the triglycerides of VLDL are hydrolyzed by LPL. After 
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the VLDL remnants dissociate from LPL contain roughly similar amounts 
of cholesterol and triglyceride. The liver removes approximately 40–60% of 
IDL by LDL receptor–mediated endocytosis via binding to apoE 
.Lipoprotein(a) [Lp(a)]   . 
         Apo(a) is synthesized in the liver and attached to apoB-100.The major 
site of clearance of Lp(a) is the liver. 
 
HDL Metabolism  
             Cholesterol in peripheral cells is transported from peripheral cells to 
the liver and intestine by a process termed "reverse cholesterol transport" 
,facilitated by HDL. 
             HDL cholesterol is transported to hepatocytes by an indirect and a 
direct pathway. HDL cholesteryl esters can be transferred to apoB-
containing lipoproteins in exchange for triglyceride CETP. The cholesteryl 
esters are then removed by LDL receptor–mediated endocytosis. HDL 
cholesterol can also be taken up directly by hepatocytes via the scavenger 
receptor class B1 (SR-B1). 
CKD and Dyslipidemia  
                     It varies according to renal function and degree of proteinuria. 
As GFR falls TGL increase and as proteinuria increases TC,TGL,LDL 
increases. 
                     Low HDL is an independent risk factor for CKD events. 28 
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According to ARIC(Atherosclerosis risk in communities) Study High 
TGL and low HDL increases the risk of CKD. 29 
   Dyslipidemia, regardless of underlying cause (DM, HT), has a role in 
progression of CKD.30 
  According to ATP (Adult Treatment program) III , in the 
management of CKD focuses on LDL as an important target.31 
  Sharma, et al 32 and Kunde et al 33 observed no hyperlipidemia in 
patients of CRF.  
        Whereas, Gupta 34 and Das et al 35 observed Hypertriglyceridemia and 
reduced High density lipoprotein (HDL). 
 
Triglyceride levels 
               Hypertriglyceridemia is partially due to  down regulation of 
lipoprotein lipase (LPL), hepatic lipase, VLDL and low-density lipoprotein 
receptor (LDL-r) expression 36 and also increased plasma apoC-III  and 
apoC-II. 37 
The down regulation of  expression of several genes 38-40 along with 
the changes in the composition of lipoprotein particles 41 represent the most 
important pathophysiological mechanisms behind the development of 
hypertriglyceridemia in CKD. 
         CKD-induced hyperparathyroidism to the pathogenesis of lipoprotein 
lipase deficiency contribute to diminished production and impaired activity 
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of lipoprotein lipase. Recurrent heparinization in the course of 
haemodialysis procedure is thought to further contribute to lipoprotein 
lipase depletion in ESRD patients.42 
 
CKD and HDL Abnormalities: 
                   The overall reduction in plasma HDL in the ESRD population 
which is due to its diminished production [43]. Serum LCAT activity and 
concentration are highly reduced in CKD patient44 due to of reduced 
production by the liver.45,46 
Also, hypoalbuminemia commonly seen in advanced CKD, may 
contribute to reduced HDL cholesterol level. 
  Reduction in HDL cholesterol in CKD is associated with elevated 
HDL triglyceride. This is due to deficiency in hepatic triglyceride lipase. 
The reduction in HDL antioxidant is most likely due to the prevailing 
Oxidative stress . 
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LDL  
            Elevated plasma LDL cholesterol concentration not a typical feature 
of patients with advanced CKD. The proportions of sdLDL and IDL, are 
increased which are athyerogenic. sdLDL is a subtype of LDL, that has high 
propensity to penetrate the vessel wall, and triggers the atherosclerotic 
process. LDL removed from the circulation mainly by macrophages. This 
leads to formation of cholesterol-laden foam cells, an important step in 
atheromatous plaque formation Expression of both scavenger receptors, SR-
A and CD36, is increased in an uremic patient.Also, uptake of unmodified 
LDL by LDL receptors is enhanced in inflammation. This also leads to foam 
cell formation and constitutes a risk factor for atherogenesis. 
 
Total cholesterol 
Plasma total cholesterol is usually normal or reduced in patients with ESRD. 
        Heavy proteinuria leads to up regulation of HMG-CoA reductase 
Therefore, heavy proteinuria, when present, can modify HMG-CoA 
reductase expression causing hypercholesterolemia in ESRD patients . 
       However, heavy proteinuria results in acquired LDL receptor 
deficiency, which plays a central role in the genesis of 
hypercholesterolemia.47,48 
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Lipoprotein [Lp(a)] 
                 Lipoprotein [Lp(a)] is an LDL-like particle whose protein moiety 
contains apolipoprotein (a) [apo(a)]. Lp(a) concentrations are genetically 
determined by the apo(a) gene. Individuals with high molecular weight have 
on average low plasma Lp(a) concentrations. 
In kidney disease, plasma Lp(a) levels are  influenced by GFR. In 
patients with large apo(a) isoforms plasma Lp(a) levels begin to increase in 
stage 1 CKD before GFR starts to decrease.49 In contrast, in patients with 
nephrotic syndrome  increase in plasma Lp(a) levels occur in all apo(a) 
isoform groups. The elevation of Lp(a) in CKD is an acquired abnormality, 
mostly influenced by the degree of proteinuria. 
It has been shown that Lp(a) is an independent risk factor for CKD 
population. Its levels are increase in CKD and especially in patients 
undergoing PD. 
 
DYSLIPIDEMIA – CONSEQUENCES: 
  Hyperlipidemia can accelerate progression of renal disease by varied 
mechanisms. Firstly, reabsorption of fatty acids, phospholipids, and 
cholesterol by tubular epithelial cells can stimulate tubulointerstitial 
inflammation and tissue injury Secondly, accumulation of lipoproteins in 
glomerular mesangium can promote matrix production and 
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glomerulosclerosis49,50. And also, impaired HDL-mediated reverse 
cholesterol transport can further contribute to tissue injury. 
        Accumulation of oxidation-prone atherogenic lipoproteins and 
defective HDL-mediated reverse cholesterol transport, which are the 
important features of uremic dyslipidemia, play a big role in the 
pathogenesis of atherosclerosis . 
 
 
 
 
 
 
  
 
 
 
 
MATERIALAS AND 
METHODS 
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4. MATERIALS AND METHODS: 
A prospective cross sectional study will be conducted among the 
CKD patients admitted in the dept. of General Medicine, Tirunelveli 
Medical college & Hospital. 
 The subjects are selected based on the inclusion and exclusion 
criteria. 
 The details of the patient are obtained in the pre-set proforma after 
getting informed consent in the regional language.  
 Routine laboratory investigations,Thyroid function tests and Lipid 
profile will be done. 
Analysis shall be made using SPSS software. 
 
Inclusion criteria: 
Patients admitted in Dept. of Medicine ,Tirunelveli Medical College 
hospital and diagnosed as Chronic kidney disease patients. 
 
Exclusion criteria: 
 Known cases of thyroid dysfunction 
 Known cases of dyslipidemia 
 Patients undergoing dialysis 
 Pregnant women 
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Study site : 
Dept. of General Medicine, Tirunelveli Medical College hospital, 
Tirunelveli. 
                                                 Sample size : 100 patients 
                                                 Study duration: 1 year 
  
  
 
 
 
 
RESULTS AND ANALYSIS 
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5. RESULTS AND ANALYSIS  
 
5.1 CKD GRADE IN STUDY POPULATION: 
CKD GRADE NO OF PATIENTS PERCENTAGE 
GRADE II 2 2% 
GRADE III 20 20% 
GRADE IV 66 66% 
GRADE V 12 12% 
 
 
 
  
2% 
20% 
66% 
12% 
CKD GRADE 
GRADE II 
GRADE III 
GRADE IV 
GRADE V 
43 
5.2 AGE DISTRIBUTION 
AGE IN YEARS NO OF PATIENTS PERCENTAGE 
< 30 13 13% 
31-40 15 15% 
41-50 28 28% 
51-60 26 26% 
> 60 18 18% 
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5.3 DISTRIBUTION OF MEAN AGE VS CKD: 
CKD GRADE 
AGE IN YEARS 
MEAN SD 
GRADE II 64 5.65 
GRADE III 43.95 14.35 
GRADE IV 48.55 13.94 
GRADE V 49.75 10.21 
ANOVA 
P VALUE - 0.179 
NON SIGNIFICANT 
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5.4 CKD PREVALENCE IN MALE AND FEMALE: 
SEX NO OF PATIENTS PERCENTAGE 
MALE 66 66% 
FEMALE 34 34% 
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5.5 SEX DISTRIBUTION IN VARIOUS GRADES OF CKD: 
 
 
 
 
 
1
 
1
8
 
4
3
 
4
 
1
 2
 
2
3
 
8
 
G R A D E  I I  G R A D E  I I I  G R A D E  I V  G R A D E  V  
SEX VS CKD 
SEX SEX 
CKD GRADE 
SEX 
MALE FEMALE 
GRADE II 1 1 
GRADE III 18 2 
GRADE IV 43 23 
GRADE V 4 8 
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5.6 PREVALENCE  OF DIABETES MELLITUS IN CKD: 
DIABETES MELLITUS NO OF PATIENTS PERCENTAGE 
PRESENT 66 66% 
ABSENT 34 34% 
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5.7 PREVALENCE  OF DIABETES MELLITUS IN  VARIOUS 
GRADES OF CKD: 
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GRADE II 0 2 
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5.8 PREVALENCE  OF HYPERTENSION IN CKD: 
HYPERTENSION NO OF PATIENTS PERCENTAGE 
PRESENT 68 68% 
ABSENT 32 32% 
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5.9 PREVALENCE  OF HYPERTENSION IN VARIOUS GRADES 
OF CKD: 
CKD GRADE 
HYPERTENSION 
PRESENT ABSENT 
GRADE II 1 1 
GRADE III 15 5 
GRADE IV 43 23 
GRADE V 9 3 
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5.10 DISTRIBUTION OF BLOOD UREA IN CHRONIC KIDNEY 
DISEASE: 
CKD GRADE 
BLOOD UREA 
MEAN SD 
GRADE II 93 12.72 
GRADE III 130.85 69.74 
GRADE IV 140.38 40.04 
GRADE V 142.44 25.6 
ANOVA 
P VALUE - 0.505 
NON SIGNIFICANT 
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5.11 DISTRIBUTION OF SERUM CREATININE IN CHRONIC 
KIDNEY DISEASE: 
CKD GRADE 
SERUM CREATININE 
MEAN SD 
GRADE II 1.2 0 
GRADE III 1.9 0.3 
GRADE IV 3.44 0.69 
GRADE V 4.94 1.75 
ANOVA 
P VALUE - 0.001 
SIGNIFICANT 
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5.12 DISTRIBUTION OF EGFR IN VARIOUS GRADES OF 
CHRONIC KIDNEY DISEASE: 
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EGFR 
MEAN SD 
GRADE II 67 1.41 
GRADE III 42.15 8.49 
GRADE IV 19.33 3.84 
GRADE V 11.75 2.41 
ANOVA 
P VALUE - 0.001 
NON SIGNIFICANT 
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5.13 DISTRIBUTION OF SERUM T3 LEVELS IN STUDY 
POPULATION: 
SERUM T3 NO OF PATIENTS PERCENTAGE 
NORMAL 88 88% 
LOW 12 12% 
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5.14 DISTRIBUTION OF SERUM T3 LEVELS IN CHRONIC 
KIDNEY DISEASE: 
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CKD GRADE 
SERUM T3 
MEAN SD 
GRADE II 1.5 0.14 
GRADE III 1 0.26 
GRADE IV 0.82 0.34 
GRADE V 0.76 0.29 
ANOVA 
P VALUE - 0.001 
SIGNIFICANT 
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5.15 DISTRIBUTION OF SERUM T4 LEVELS IN CHRONIC 
KIDNEY DISEASE: 
 
SERUM T4 NO OF PATIENTS PERCENTAGE 
NORMAL 11 11% 
LOW 89 89% 
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5.16 DISTRIBUTION OF SERUM T3 LEVELS IN  VARIOUS 
GRADES OF CHRONIC KIDNEY DISEASE: 
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GRADE II 7.05 0.77 
GRADE III 3.79 0.72 
GRADE IV 2.59 1.07 
GRADE V 2.48 0.99 
ANOVA 
P VALUE - 0.006 
SIGNIFICANT 
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5.17 DISTRIBUTION OF SERUM TSH LEVELS IN CHRONIC 
KIDNEY DISEASE: 
SERUM TSH NO OF PATIENTS PERCENTAGE 
NORMAL 12 12% 
ABNORMAL 88 88% 
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5.18 DISTRIBUTION OF SERUM TSH LEVELS IN VARIOUS 
GRADES OF CHRONIC KIDNEY DISEASE: 
CKD GRADE 
SERUM TSH 
MEAN SD 
GRADE II 7.92 0.59 
GRADE III 9.1 2.78 
GRADE IV 10.87 2.45 
GRADE V 11.39 2.17 
ANOVA 
P VALUE - 0.001 
SIGNIFICANT 
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5.19 DISTRIBUTION OF TOTAL CHOLESTEROL LEVELS IN 
CHRONIC KIDNEY DISEASE: 
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N O R M A L  H I G H  
TOTAL CHOLESTEROL 
TOTAL CHOLESTEROL NO OF PATIENTS PERCENTAGE 
NORMAL 26 26% 
HIGH 74 74% 
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5.20 DISTRIBUTION OF TOTAL CHOLESTEROL LEVELS IN 
VARIOUS GRADES OF CHRONIC KIDNEY DISEASE 
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G R A D E  I I  G R A D E  I I I  G R A D E  I V  G R A D E  V  
MEAN TOTAL CHOLESTEROL 
CKD GRADE 
TOTAL CHOLESTEROL 
MEAN SD 
GRADE II 182.58 17.67 
GRADE III 202.55 19.28 
GRADE IV 236.79 35.96 
GRADE V 255.25 34.94 
ANOVA 
P VALUE - 0.001 
SIGNIFICANT 
62 
5.21 DISTRIBUTION OF TRIGLYCERIDES LEVELS IN CHRONIC 
KIDNEY DISEASE 
TRIGLYCERIDES NO OF PATIENTS PERCENTAGE 
NORMAL 87 87% 
HIGH 13 13% 
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5.22 DISTRIBUTION OF TRIGLYCERIDES LEVELS IN VARIOUS 
GRADES OF CHRONIC KIDNEY DISEASE 
CKD GRADE 
TRIGLYCERIDES 
MEAN SD 
GRADE II 148 5.65 
GRADE III 162.3 32.79 
GRADE IV 181 52.99 
GRADE V 195.33 13.32 
ANOVA 
P VALUE - 0.171 
NON SIGNIFICANT 
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5.23 DISTRIBUTION OF HIGH DENSITY LIPOPROTEINS LEVELS 
IN CHRONIC KIDNEY DISEASE 
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5.24 DISTRIBUTION OF HIGH DENSITY LIPOPROTEINS LEVELS 
IN VARIOUS LEVELS OF CHRONIC KIDNEY DISEASE 
CKD GRADE 
HIGH DENSITY LIPOPROTEIN 
MEAN SD 
GRADE II 52.6 5.65 
GRADE III 40.2 10.79 
GRADE IV 36.35 3.18 
GRADE V 31.08 3.47 
ANOVA 
P VALUE - 0.001 
SIGNIFICANT 
 
 
 
 
52.6 
40.2 
36.35 
31.08 
0 
10 
20 
30 
40 
50 
60 
GRADE I I  GRADE I I I  GRADE IV  GRADE V  
MEAN HDL 
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5.25 DISTRIBUTION OF LOW DENSITY LIPOPROTEINS LEVELS 
IN CHRONIC KIDNEY DISEASE 
 
 
 
 
 
 
 
 
 
  
38% 
62% 
LDL 
NORMAL 
ABNORMAL 
LDL NO OF PATIENTS PERCENTAGE 
NORMAL 38 38% 
ABNORMAL 62 62% 
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5.26 DISTRIBUTION OF HIGH DENSITY LIPOPROTEINS LEVELS 
IN VARIOUS  GRADES OF CHRONIC KIDNEY DISEASE 
 
 
 
 
132.5 
144.55 
151.76 
163.3 
GRADE II GRADE III GRADE IV GRADE V 
MEAN LDL 
CKD GRADE 
LOW DENSITY LIPOPROTEIN 
MEAN SD 
GRADE II 132.5 17.67 
GRADE III 144.55 19.76 
GRADE IV 151.76 29.04 
GRADE V 163.3 22.76 
ANOVA 
P VALUE - 0.199 
NON SIGNIFICANT 
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5.27 DISTRIBUTION OF VERY LOW DENSITY LIPOPROTEINS 
LEVELS IN CHRONIC KIDNEY DISEASE 
 
VLDL NO OF PATIENTS PERCENTAGE 
NORMAL 39 39% 
ABNORMAL 61 61% 
 
 
 
 
 
 
 
 
39% 
61% 
VLDL 
NORMAL 
ABNORMAL 
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5.28 DISTRIBUTION OF VERY LOW DENSITY LIPOPROTEINS 
LEVELS IN VARIOUS GRADES OF CHRONIC KIDNEY DISEASE 
CKD GRADE 
VLDL 
MEAN SD 
GRADE II 16.5 2.12 
GRADE III 38.85 8.46 
GRADE IV 56.52 17.21 
GRADE V 63.33 15.66 
ANOVA 
P VALUE - 0.423 
NON SIGNIFICANT 
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6. DISCUSSION 
  The motto of the present study was to predict the prevalence of 
thyroid dysfunction & Lipid abnormalities in CKD patients  
  To determine the pathological interrelationship between thyroid 
dysfunction and severity of renal disease, numerous studies were conducted 
about thyroid function abnormality and severity of CKD and different 
results have been shown. 
In our study, only those CKD patients on conservative line of therapy 
were studied. This can be attributed to the fact that thyroid profile undergoes 
changes due to dialysis independent of the presence due to chronic kidney 
disease. Numerous studies have been studied by comparing CKD patients 
on conservative line of management and patients on HD by Ramirez51 and 
Kayima et al52. 
In our study, 100 patients of CKD, who were on conservative 
management fulfilling the criteria for CKD were studied, among these 100 
patients, 66 were males and 34 were females, their age distribution varied 
from <30 yrs to >60 years. Among these 100 patients, patients were 
categorized into <30 yrs, 31-40 yrs, 41-50 yrs, 51-60 yrs,>60yrs. 
  Among the 100 patients in our study, 66% of patients were males and 
34% patients were females. 
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  Of the 100 patients, the mean eGFR ranged from 67ml/min in Stage 
II CKD  to 11.75 ml/min in Stage V CKD in our study. 
The blood urea mean value ranged from 93 mg/dl in stage II CKD to 
142.44 mg/dl in stage V CKD. 
The creatinine mean values varied from 1.2 mg/dl in stage II CKD to 
4.9 mg/dl in stage V CKD. 
In our study out of 100 patients, 12 patients had low serum T3 levels 
(12%).  
89 patients had low T4 levels in our study (89%). 
88 patients had low TSH (88%) and 12 had normal range TSH. 
  In our study, the decreasing trend in T4 and increasing Trend in TSH 
showed linear correlation with progressing stages of CKD. 
One study done by Spector 53 and Ramirez et al 51 Dudani et al54, 
Karunanidhi et al55. These studies showed abnormality in hypophyseal 
mechanism of TSH release in  patients with Uraemia as the TSH response to 
the TRH was reduced. 
 Another study which was done  by Joseph et al and Hardy etal 
showed up low T3 T4 level with high TSH level indicating maintenance of 
pituitary thyroid axis. Several studies in CKD patients showed low T3 
values. Low T3 had also been reported in Ramirez et al51, Hegedus et a1, 
Beckett et al56PonAjil Singh et al, P Iglesias and JJ Diez  and many others. 
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Ramirez and Spector et a153 study exposed the linear correlation between 
mean serum T3 and T4 and severity of CKD 
  Studies by Quionverdeet a157 showed high preponderance of 
hypothyroidism in CKD. It was roughly estimated to be about 5% in 
patients with final stage of CKD. 
  Detailed study by Kaptein et al58 showed the prevalence of primary 
hypothyroidism was about 2.5 times much  higher in chronic kidney disease 
and dialysis than in normal population. The incidence of hypothyroidism in 
CKD was estimated to range in between 0 and 9.5% 
  Kaptein study also calculated the presence of anti thyroid antibody 
titer in 6.7% of CKD. 
  The symptoms of hypothyroidism were distributed equally in both 
hypothyroid and CKD patients in our study. 
So, diagnosis of hypothyroidism in CKD more importantly depends 
on TSH level which must be very high (>20 µIU/dl) with low level of serum 
T4. In this study, none of the patients had clinical or biochemical features of 
hyperthyroidism. 
  As a go  with other studies, mean T3 level in our study was decreased  
in GFR less than 15 ml/min. In patients with reduced  GFR, T3 level was 
found to be reduced and it shows that there was straight line relationship 
between level of T3,T4 and GFR, which is consistent with Avinashi et al 
study. 
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GOITRE: 
  Study by Ramirez et a151 showed high prevalence of goiter in patients 
with CKD especially those undergoing chronic dialysis. The incidence was 
found to be raised in end stage renal disease. The possible explanation could 
be due to accumulation of iodides in Thyroid gland due to reduced renal 
clearance in CKD patients. Other than goiter, study conducted  by Hegedus 
et al  showed the volume of thyroid gland was significantly increased in 
patients with CKD. In our study, no patient had goitre. 
 
CKD AND LIPID 
In our study, most frequent lipid abnormalities d o c u m e n t e d  
w ere low HDL levels and hypercholesterolemia. 
 
DECREASED HIGH DENSITY LIPOPROTEIN LEVELS 
 In our study, 56 out of 100 patients with CKD had low levels of 
HDL. 
The low HDL levels in patients with chronic kidney disease in our 
study were in match with Diana M Lee LG et al 59 who studied the 
abnormalities of lipid profile in CRF patients. 
             This low HDL cholesterol levels was also an isolated independent 
risk factor for the development of CKD in the Framingham  spring study. 
Several pathological processes may underlie the reductions in HDL 
cholesterol levels, which is usually an indication of d y s f u n c t i o n a l  
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reverse cholesterol transport. Apo AI, which is the activator of lecithin 
cholesterol acyltransferase (LACT), is decreased in CKD due to inverse 
regulation of hepatic Apo AI genes causing a decline in the function of 
LACT, which leads to decreased cholesterol esterification and abnormality 
in HDL maturation. The activity of LACT is persistently decreased in 
CKD, so there is reduced HDL levels. 
In a study by MDRD, low HDL levels in CKD patients were one 
of the independent risk factor for progression of kidney disease.  In our 
study the mean value was significantly lower than the age matched 
healthy controls. 
  
ELEVATED RIGLYCERIDES 
Triglyceride levels were essentially elevated in our study than in 
control group. Abnormal triglyceride values were found in 13 out of 100  
patients in our study. The present study demonstrates that CRF is 
commonly accompanied by lipid d y s f u n c t i o n  manifesting as 
hypertriglyceridemia.  
This is in co-ordinance to the observations made in Western 
studies and recent Indian  studies60,61,62,63   by  Gupta  DK,Das  BS  
and  Bagdae  J.  Elevated triglyceride levels are implicated to impaired 
activity lipoprotein lipase  (LPL)64 and direct inhibitory action  of 
various uremic ‘toxins’ on the enzymes involved in lipid metabolism65 
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pinpointing the most important pathophysiological mechanisms causing 
the development of hypertriglyceridemia in renal failure. 
Chan MK et al  also showed hypertriglyceridemia was the major 
abnormality in their studies. Hypertriglyceridemia may represent an early 
feature of renal failure. 
 
ELEVATED LOW DENSITY LIPOPROTEIN & VERY LOW 
DENSITY LIPOPROTEIN: 
LDL was e s s e n t i a l l y  elevated c o mp a r e d  t o  that of controls 
in our study. We found that  6 2  o f  1 0 0  of patients showed elevated 
LDL levels and in our study 61 out of 100 patients showed raised LDL 
levels. Most studies point out that Uraemic Patients commonly have 
normal to slightly decreased concentrations of LDL-C levels and they 
exhibit significant disturbance in the density distribution of LDL sub 
fraction that is characterized by presence of predominantly small dense 
LDL particles.66 
In  the  present  study,  we  find  significantly  high  levels  of LDL  
cholesterol in the group with CKD stages IV & V 
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TOTAL CHOLESTEROL 
Total cholesterol levels were raised in 74 out of 100 patients in our 
study group with CKD results in acquired LDL receptor deficiency, 
which plays a vital role in the cause of associated hypercholesterolemia. 
67
 
Correlation Studies: 
  It was found that abnormal serum triglycerides, TC, HDL, were 
found to be increased significantly in the group of eGFR between CKD 
stage 3,4,and 5 
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7. CONCLUSION 
In my study population, 100 CKD patients who were on conservative 
line management were studied. Among them 88% the patients had high 
TSH values,12% had low T3values & 89% had low T4 values. 
                The modification in the serum levels of T3 and T4 in patients with 
CKD can be considered  protective mechanism, favouring conservation of 
protein. 
There is progressive increase in count of patients with a decreasing 
T3 and T4 and increasing TSH  proportional to the severity of renal failure. 
There is also increase in incidence of hypothyroidism found in 
patients with chronic kidney disease. 
As the age progresses, there is increase in incidence of Low T3 
syndrome in patients with CKD. 
In patients with low GFR the serum T3,T4 levels was found to be 
low. This shows a direct linear relationship between GFR and T3,T4 
levels. 
HDL levels were reduced and triglycerides, total cholesterol and 
TGL levels, LDL, VLDL were raised in the study group in comparison to 
the controls. 
              There is a statistically significant rise in the level of serum 
triglycerides, serum LDL, serum VLDL in CKD grade III,IV and V 
patients. 
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              There was a negative correlation between serum HDL  level and 
GFR levels which was statistically essential & significant. 
 All the lipid abnormalities found in CKD were reduced HDL-C 
levels in serum along with a significant rise in Serum triglyceride, serum 
cholesterol  serum LDL level and serum VLDL level. 
  
 
 
 
 
 
ANNEXURES 
  
79 
8. ANNEXURES 
PROFORMA 
S. No          : 
Name       :  Weight  : 
Age/Sex   : Height  : 
Occupation : BMI : 
Address    : 
History : 
Diabetes Mellitus : 
Hypertension : 
Clinical examination : 
 
Investigations:                                                                           Ref values 
Complete Blood Count: 
 TC: 
 DC  : P %; L  %;  E %; M      %; B% 
 TRBC : 
 Hb  : 
 PCV  : 
 PLT  : 
 ESR  :                  mm in ½ hr 
          mm in 1 hr 
Blood sugar: 
Renal function tests: 
 Bld. Urea :  15-40 mg% 
 Se. Creatinine :  0.2-1.2 mg% 
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Serum electrolytes: 
 Na+  :    135-145mEq/l 
 K+  :    3.5-5.5 mEq/l 
Thyroid function tests ( method)         Reference Value 
 T3 -  0.5-2.0 ng/ml 
 T4 -  4.4-11.6 IU/L 
 TSH -  0.5-7.0 mmol/L 
Lipid Profile: 
 Total cholesterol - 150-200 mg/dl 
 Triglycerides - 70-200 mg/dl 
 HDL  - 35-60 mg/dl 
VLDL - 0-40 mg/dl 
LDL - 70-130 mg/dl 
USG Abdomen & Pelvis: 
Other investigations: 
∆: CHRONIC KIDNEY DISEASE -  STAGE  -    
eGFR=186×(creatinine in µmol/L/88.4)-1.154×(age in yrs)-0.203 × (0.742 if female) × (1.21if black) 
STAGE eGFR  
1 >90  
2 60-89  
3 30-59  
4 15-29  
5 <15 or on dialysis  
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Study of Thyroid and Lipid Profile in 
Chronic Kidney Disease 
S. No         : 
Name        :   
Age/Sex  : 
∆ : 
Renal function tests: 
Blood. Urea  :  
Serum. Creatinine  : 
 
Thyroid function tests ( method :          ) 
 T3- 0.5-2.0 ng/ml 
 T4- 4.4-11.6 IU/L 
 Free T3- 
 Free T4- 
 TSH- 0.5-7.0 mmol/L 
 
Lipid Profile: 
 Total cholesterol- 150-200 mg/dl 
 Triglycerides- 70-200 mg/dl 
 HDL-  35-60 mg/dl 
VLDL- 10-40 mg/dl 
LDL- 70-130 mg/dl 
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  S.NO NAME AGE SEX
SEX 
CODE
DIABET
ES
DM 
CODE
HYPERTE
NSION
HT 
CODE
  EGFR
CKD 
GRADE
GRADE 
CODE
UREA
CREATIN
INE
   T3   T4 TSH
TOTAL 
CHOLESTROL
TGL HDL LDL VLDL
1 KRISHNAMOORTHY 62 MALE 1 + 1 + 1 16 IV 4 100 4.2 1.8 1.22 8.8 120 174 40 125 80
2 MUTHUKUMAR 60 MALE 1 - 2 - 2 66 II 2 84 1.2 1.6 7.6 7.5 195 144 56 145 18
3 CHELLATHURAI 65 MALE 1 + 1 + 1 21 IV 4 135 3.2 0.5 2.2 8.6 210 185 37 128 35
4 HARIKRISHNAN 53 MALE 1 + 1 + 1 16 IV 4 100 4.2 0.7 1.32 8.1 265 175 36 172 43
5 KOVILPITCHAI 68 FEMALE 2 - 2 + 1 68 II 2 102 1.2 1.4 6.5 8.34 170 152 48 120 15
6 KANAPATHI 60 MALE 1 + 1 - 2 15 IV 4 79 4.3 1.1 2.32 11.5 231 167 31 168 21
7 KARIPASAMY 40 MALE 1 + 1 + 1 29 IV 4 116 2.59 1.5 2.54 8.6 210 176 43 125 32
8 SUDALAIMANI 55 MALE 1 - 2 + 1 54 III 3 76 1.48 1.9 3.34 12.2 163 241 32 140 34
9 MURUGAN 54 MALE 1 + 1 + 1 12 V 5 106 5.5 0.7 2.1 10.8 258 203 26 129 80
10 THANGAVEL 39 MALE 1 + 1 + 1 6 V 5 105 10.1 1.2 2.5 14.5 243 204 28 174 65
11 LAKSHMANAN 64 MALE 1 - 2 + 1 55 III 3 74 1.39 1.32 3.1 8.13 195 165 56 142 42
12 GANAPATHY 70 MALE 1 + 1 + 1 45 III 3 87 1.65 1.1 3.7 16.7 210 170 36 140 45
13 KALIAPPAN 42 MALE 1 + 1 - 2 19 IV 4 136 3.8 1 1.56 12.7 235 175 35 153 54
14 AZHAGAR 57 MALE 1 + 1 - 2 25 IV 4 164 2.8 1.8 2.65 10.2 210 173 40 125 65
15 SANJEEVI 56 MALE 1 + 1 + 1 16 IV 4 25 4.1 0.7 4.2 7.12 220 160 38 142 58
16 CHINAMARIMUTHU 50 MALE 1 - 2 + 1 38 III 3 15.6 2 0.9 4.3 7.98 205 135 43 143 41
17 MOHAMMED ISHMAIL 22 MALE 1 + 1 - 2 23 IV 4 21.2 3.6 0.7 2.1 8.09 202 187 34 123 47
18 SANKARAN 53 MALE 1 + 1 + 1 32 III 3 83 2.3 1 4.2 6.6 182 102 29 123 32
19 POOVATHIAMMAL 52 FEMALE 2 + 1 - 2 25 IV 4 204 2.17 1.5 2.43 12.3 228 209 39 125 41
20 SAKTHIVEL 42 MALE 1 - 2 + 1 16 IV 4 150 4.4 0.8 2 7.89 231 190 42 123 38
21 AMALRAJ 39 MALE 1 - 2 + 1 58 III 3 22.6 1.45 1.2 3.3 8.98 195 162 33 122 21
22 SUTHANTHINAKODI 40 MALE 1 + 1 + 1 42 III 3 328 1.9 1 4 8.8 198 170 36 120 34
23 MOHAN 38 MALE 1 + 1 + 1 17 IV 4 99 4.18 0.6 1.62 7.7 235 160 38 142 22
24 MURUGAIAH 51 MALE 1 + 1 + 1 16 IV 4 168 4.2 0.9 1.34 8.8 224 574 42 185 210
25 SADACHARAVEL 44 MALE 1 + 1 + 1 42 III 3 195 1.89 1 4.56 7.67 199 144 50 128 22
26 VINAYAGAM 58 MALE 1 + 1 - 2 20 IV 4 183 3.45 0.7 2.98 8.8 209 230 44 196 46
27 MARY 56 FEMALE 2 + 1 - 2 19 IV 4 156 2.8 1 4.9 6.8 243 198 32 128 32
28 KARUPAYI 50 FEMALE 2 + 1 - 2 12 V 5 292 4.1 0.7 3.4 10.4 278 175 35 180 79
29 paulthai 44 FEMALE 2 + 1 + 1 14 V 5 96 3.76 1.1 2.2 11.6 284 184 34 183 39
30 vijaya 34 FEMALE 2 - 2 - 2 15 IV 4 126.6 3.6 0.6 2.2 109 257 186 34 128 35
31 muthathal 55 FEMALE 2 + 1 + 1 24 IV 4 89 2.22 0.7 3.2 8.5 233 194 32 154 64
32 mohaideen fathima 62 FEMALE 2 + 1 + 1 20 IV 4 94 2.54 0.7 2.1 6.4 254 192 37 125 53
33 suvisesamuthu 62 MALE 1 + 1 - 2 24 IV 4 160 2.85 0.5 2.4 8.3 233 178 39 121 47
34 subbai 51 MALE 1 + 1 + 1 15 IV 4 175.8 4.5 0.7 3.2 6.7 243 178 41 119 39
35 SUBBULAKSHMI 20 FEMALE 2 + 1 + 1 19 IV 4 184 3.3 1.6 2.8 7.4 245 204 32 122 49
36 SANKAR 40 MALE 1 + 1 - 2 14 V 5 143 5 0.8 2.5 10.8 204 214 30 172 67
37 LINGAM 89 MALE 1 + 1 + 1 18 IV 4 165 3.5 0.9 1.84 14.8 156 182 37 168 58
38 PUSHBARANI 44 FEMALE 2 + 1 + 1 18 IV 4 176.9 3 0.7 2.92 9.5 300 176 39 123 57
39 CHINNAPANDI 40 MALE 1 - 2 + 1 34 III 3 173 2.3 0.9 3.4 7.89 204 177 50 154 44
40 MARIAMMAL 35 FEMALE 2 - 2 - 2 16 IV 4 94 3.45 1.6 3.6 9.5 295 184 32 165 68
41 MALATHI 24 FEMALE 2 - 2 + 1 26 IV 4 128.6 2.43 0.8 1.5 11.4 287 204 37 125 46
42 NARAYANAMOORTHY 55 MALE 1 + 1 + 1 20 IV 4 182 3.49 1.2 3.4 12.1 268 184 39 124 44
43 PRIYADHARSHINI 74 FEMALE 2 + 1 - 2 12 V 5 95.7 3.76 0.4 1.9 12.5 238 194 34 173 68
44 YOUSEPH 50 MALE 1 - 2 + 1 15 IV 4 87.6 4.56 0.7 2.54 7.8 194 144 37 173 33
45 ELAMATHI 27 FEMALE 2 - 2 + 1 22 IV 4 162 2.7 0.8 1.76 8.7 202 189 40 126 34
46 VADHINI 39 FEMALE 2 + 1 + 1 15 IV 4 135.7 3.6 0.6 1.54 11.4 190 159 33 175 32
47 POOMARI 50 FEMALE 2 + 1 - 2 16 IV 4 183 3.3 0.9 1.76 9.6 276 210 38 174 31
48 SALARAJAN 25 MALE 1 - 2 + 1 18 IV 4 174 4.4 1.1 2.07 11.3 298 157 32 165 41
49 KUMAR 23 MALE 1 + 1 + 1 42 III 3 113.8 2.1 1.1 3.04 9.6 203 178 33 129 42
50 MALLIKA 40 FEMALE 2 + 1 + 1 12 V 5 103.6 4.5 0.3 2.9 14.5 210 196 30 128 69
51 LAKSHMI 55 FEMALE 2 + 1 + 1 15 IV 4 94.5 3.3 0.9 3 12.6 256 184 36 166 37
52 SORNAM 60 FEMALE 2 + 1 + 1 8 V 5 156 5.5 1.1 3.67 9.4 278 188 35 187 39
53 MUPPIDATHI 45 FEMALE 2 + 1 - 2 15 IV 4 178 3.78 0.9 1.76 14.3 269 159 37 167 43
54 GANESHSANKAR 25 MALE 1 - 2 - 2 46 III 3 146.4 1.9 0.9 4.98 15.3 263 138 38 138 33
55 VAIRAMUTHU 70 MALE 1 + 1 + 1 16 IV 4 159 3.89 1.2 3.76 8.5 274 196 37 128 36
56 RAMALAKSHMI 30 FEMALE 2 - 2 + 1 15 IV 4 103.6 3.79 0.9 4.5 12.2 200 164 34 188 37
57 GAYATHRI 14 FEMALE 2 - 2 + 1 15 IV 4 134 4.5 0.8 1.7 10.5 194 188 40 186 43
58 JANANOSHAN 39 MALE 1 - 2 + 1 21 IV 4 165 3.5 0.9 3.9 7.9 198 207 38 187 53
59 FATHIMA BEEVI 65 FEMALE 2 + 1 + 1 17 IV 4 152 2.89 0.9 4.6 11.4 202 189 39 174 65
60 BASKAR 55 MALE 1 + 1 - 2 35 III 3 89 2.1 0.6 4.7 7.6 200 178 57 175 55
61 RAVIAPPAN 71 MALE 1 - 2 - 2 18 IV 4 193.5 3.5 0.6 2.7 5.8 193 174 37 178 84
62 SHANMUGASUNDHARAM 63 MALE 1 + 1 + 1 27 IV 4 186 2.57 0.8 4.8 11.2 255 126 38 198 54
63 NARAYANAN 45 MALE 1 + 1 1 41 III 3 174 1.89 0.9 2.5 6.8 196 133 33 178 44
64 ARULNATHAN 61 MALE 1 + 1 + 1 23 IV 4 114 3 0.4 3.2 12.6 292 188 31 189 45
65 ANTONYAMMAL 57 FEMALE 2 + 1 + 1 12 V 5 108.5 4 0.7 2.5 9.4 295 185 34 162 66
66 KALYANI 55 FEMALE 2 - 2 + 1 22 IV 4 132 2.45 0.8 3.8 5.8 228 163 36 174 35
67 CHINNASAMY 45 FEMALE 2 - 2 + 1 24 IV 4 175 2.3 0.8 3.9 9.3 256 184 37 163 35
68 ARUNACHALLATHAMMAL 60 FEMALE 2 + 1 - 2 23 IV 4 142 2.3 0.4 2.2 7.9 222 173 40 126 54
69 PANDIAN 64 MALE 1 - 2 + 1 25 IV 4 94 2.7 0.5 2.2 6.8 245 183 36 276 64
70 MUTHUSAMY 45 MALE 1 + 1 - 2 20 IV 4 191.7 3.6 0.8 3.5 8.1 236 185 37 174 64
71 GNANAPRAKASAM 45 MALE 1 + 1 - 2 22 IV 4 132.8 3.3 0.6 3.2 9.3 276 152 34 124 35
72 CHINNAKANNI 49 MALE 1 - 2 + 1 15 IV 4 185 4.4 0.8 2.2 9.5 298 158 33 123 36
73 SANKARVIGNESH 30 MALE 1 + 1 - 2 40 III 3 193 2.1 1.1 2.8 8.7 194 118 56 176 44
74 RAKKAIAH 45 MALE 1 + 1 - 2 19 IV 4 124 3.76 0.9 2.5 7.8 265 159 31 174 37
75 ARULJOYHI 38 FEMALE 2 - 2 + 1 32 III 3 163.7 1.89 0.9 4 6.7 222 173 38 164 45
76 PITCHAMMAL 58 FEMALE 2 + 1 - 2 31 III 3 139 1.8 1 3.7 8.4 204 190 49 142 46
77 SEKAR 49 FEMALE 2 - 2 + 1 14 V 5 152 3.6 0.4 4.2 8.4 203 209 30 179 76
78 MAREAMMAL 50 FEMALE 2 + 1 + 1 18 IV 4 166.5 2.9 0.3 3.2 8.9 198 126 32 163 55
79 KRISHNASAMY 65 MALE 1 + 1 - 2 19 IV 4 182 3.5 1.3 1.8 12.5 194 190 33 175 43
80 THIRUMANI 52 MALE 1 + 1 - 2 15 IV 4 163 4.5 0.4 1.08 6.7 243 173 36 123 76
81 SIVAMURUGAN 40 MALE 1 - 2 + 1 25 IV 4 117.8 3 0.6 2.87 8.6 254 134 37 163 85
82 ESWARAPILLAI 54 MALE 1 - 2 + 1 26 IV 4 162 2.7 0.8 3.35 9.5 265 173 38 121 556
83 SENTHILKUMAR 45 MALE 1 + 1 - 2 41 III 3 159 1.9 0.9 4 7.6 232 112 49 122 45
84 MARIMUTHU 27 MALE 1 + 1 + 1 17 IV 4 132.8 4.4 0.4 2.3 9.5 245 142 35 154 34
85 MUTHULAKSHMI 29 MALE 1 + 1 + 1 24 IV 4 183 3.27 1.1 3 13.2 273 175 33 132 23
86 KANAGAMANI 45 FEMALE 2 - 2 + 1 12 V 5 172 4.4 0.9 1.34 14.6 275 213 32 168 38
87 MOHAMED HASIM 10 MALE 1 + 1 + 1 45 III 3 96 2.3 0.8 3 7.3 199 194 34 165 31
88 CHINNATHAMBI 45 MALE 1 + 1 + 1 19 IV 4 104.7 3.7 0.4 0.6 9.8 206 156 35 158 54
89 ARUMUGAM 39 MALE 1 + 1 + 1 16 IV 4 119 4.3 1.1 0.2 6.4 265 174 35 173 37
90 KANNAN 45 MALE 1 - 2 + 1 13 V 5 179.5 5.1 0.9 0.6 9.8 297 179 25 125 74
91 GANESHAN 45 MALE 1 - 2 + 1 33 III 3 126 2.3 0.9 5 11.7 198 184 15 165 43
92 RAKKAIAH 45 MALE 1 - 2 + 1 17 IV 4 94 4 0.6 0.78 14 198 173 38 156 48
93 VELLAMMAL 55 MALE 1 - 2 + 1 17 IV 4 105 3.9 0.7 4.45 11.8 243 147 39 129 59
94 SAMUTHIRAPANDI 63 MALE 1 + 1 - 2 22 IV 4 193 3.1 0.5 3.4 6.9 276 146 38 119 65
95 ARUNACHALLAM 65 MALE 1 + 1 - 2 24 IV 4 153 2.8 0.3 2.2 8.5 254 185 38 121 43
96 SELVAM 50 MALE 1 - 2 + 1 15 IV 4 129.8 4.5 0.9 4 7.9 234 165 31 121 29
97 SOLAIAMMAL 49 FEMALE 2 + 1 _ 2 24 IV 4 99 2.3 1.1 2.4 7.9 198 174 32 142 34
98 KALA 60 FEMALE 2 - 2 - 2 15 IV 4 152.6 3.6 0.4 3.4 7.6 276 154 33 165 23
99 ARUMUGAM 46 MALE 1 + 1 + 1 17 IV 4 198 4 0.3 0.43 8.4 243 173 35 158 54
100 JOSEP 50 MALE 1 + 1 + 1 57 III 3 163 1.39 0.7 4.2 7.5 189 182 37 125 34
